Clinical Trials Logo

Any Advanced Solid Tumors clinical trials

View clinical trials related to Any Advanced Solid Tumors.

Filter by:
  • None
  • Page 1

NCT ID: NCT04332653 Active, not recruiting - Ovarian Cancer Clinical Trials

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Start date: June 10, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The main purposes of Phase 1b of this study are to determine the following in participants with advanced solid tumors: - Safety and tolerability of NT-I7 in combination with pembrolizumab - Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) The main purpose of Phase 2a of this study is to assess the preliminary anti-tumor activity of NT-I7 in combination with pembrolizumab in participants with checkpoint inhibitor (CPI) treated and naïve relapsed and refractory (R/R) tumors. The main purpose of the Biomarker Cohort is to assess a potential correlation between tumor infiltrating lymphocytes (TILs) and clinical benefits in participants with CPI-naïve R/R ovarian cancer (OC).